HC Wainwright reaffirmed their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO - Free Report) in a research report released on Wednesday,Benzinga reports. The firm currently has a $23.00 target price on the stock. HC Wainwright also issued estimates for Lexeo Therapeutics' Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.
A number of other research firms have also issued reports on LXEO. Leerink Partners lowered their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, March 24th. Royal Bank of Canada reduced their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and an average target price of $22.80.
Get Our Latest Stock Analysis on Lexeo Therapeutics
Lexeo Therapeutics Stock Performance
Shares of LXEO stock traded down $0.01 during trading hours on Wednesday, reaching $4.10. The stock had a trading volume of 322,531 shares, compared to its average volume of 345,505. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a 50-day simple moving average of $4.05 and a 200-day simple moving average of $6.56. The firm has a market capitalization of $136.11 million, a PE ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.50.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.09. As a group, equities analysts forecast that Lexeo Therapeutics will post -3.14 earnings per share for the current year.
Institutional Investors Weigh In On Lexeo Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in LXEO. Frazier Life Sciences Management L.P. acquired a new stake in Lexeo Therapeutics in the third quarter valued at approximately $11,307,000. Janus Henderson Group PLC raised its holdings in shares of Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company's stock valued at $33,997,000 after purchasing an additional 599,203 shares in the last quarter. Altium Capital Management LLC bought a new stake in Lexeo Therapeutics in the fourth quarter worth $2,665,000. Point72 Asset Management L.P. increased its position in Lexeo Therapeutics by 102.5% during the fourth quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company's stock worth $4,937,000 after buying an additional 379,828 shares during the last quarter. Finally, Verition Fund Management LLC raised its holdings in Lexeo Therapeutics by 84.5% during the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company's stock valued at $7,027,000 after buying an additional 355,928 shares in the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.
Lexeo Therapeutics Company Profile
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Further Reading
Before you consider Lexeo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.
While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
